Cargando…

Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity

SARS-CoV-2 has caused the COVID-19 pandemic. B.1.617 variants (including Kappa and Delta) have been transmitted rapidly in India. The transmissibility, pathogenicity, and neutralization characteristics of these variants have received considerable interest. In this study, 22 pseudotyped viruses were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Li, Li, Qianqian, Wu, Jiajing, Yu, Yuanling, Zhang, Yue, Nie, Jianhui, Liang, Ziteng, Cui, Zhimin, Liu, Shuo, Wang, Haixin, Ding, Ruxia, Jiang, Fei, Li, Tao, Nie, Lingling, Lu, Qiong, Li, Jiayi, Qin, Lili, Jiang, Yinan, Shi, Yi, Xu, Wenbo, Huang, Weijin, Wang, Youchun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Coronaviruses
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9004538/ https://www.ncbi.nlm.nih.gov/pubmed/35293847 http://dx.doi.org/10.1080/22221751.2022.2054369

Ejemplares similares

A second functional furin site in the SARS-CoV-2 spike protein
por: Zhang, Yue, et al.
Publicado: (2022)

Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1
por: Liu, Shuo, et al.
Publicado: (2023)

Development of an automated, high-throughput SARS-CoV-2 neutralization assay based on a pseudotyped virus using a vesicular stomatitis virus (VSV) vector
por: Liang, Ziteng, et al.
Publicado: (2023)

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination
por: Wang, Meiyu, et al.
Publicado: (2021)

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron
por: Zhang, Li, et al.
Publicado: (2021)

Cellular tropism and antigenicity of mink-derived SARS-CoV-2 variants
por: Zhang, Li, et al.
Publicado: (2021)

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization
por: Zhang, Li, et al.
Publicado: (2021)

Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses
por: Li, Qianqian, et al.
Publicado: (2022)

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice
por: Li, Xingxing, et al.
Publicado: (2022)

The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
por: Wu, Jiajing, et al.
Publicado: (2021)

ACE2 decoy receptor generated by high-throughput saturation mutagenesis efficiently neutralizes SARS-CoV-2 and its prevalent variants
por: Wang, Bolun, et al.
Publicado: (2022)

The antigenicity of SARS-CoV-2 Delta variants aggregated 10 high-frequency mutations in RBD has not changed sufficiently to replace the current vaccine strain
por: Wu, Jiajing, et al.
Publicado: (2022)

Heterologous booster with inhaled adenovirus vector COVID-19 vaccine generated more neutralizing antibodies against different SARS-CoV-2 variants
por: Zhong, Jiaying, et al.
Publicado: (2022)

Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants
por: Zhao, Zhuxiang, et al.
Publicado: (2022)

Effectiveness of vaccination in reducing hospitalization and mortality rates in dialysis patients with Omicron infection in China: A single-center study
por: Zhang, Quanchao, et al.
Publicado: (2023)

Reduced neutralization of SARS-CoV-2 B.1.617 variant by convalescent and vaccinated sera
por: Hu, Jie, et al.
Publicado: (2021)

Clinical features, diagnosis, and management of COVID-19 vaccine-associated Vogt-Koyanagi-Harada disease
por: Xu, Ke, et al.
Publicado: (2023)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
por: Liu, Chang, et al.
Publicado: (2021)

Candidate Multi-Epitope Vaccine against Corona B.1.617 Lineage: In Silico Approach
por: Seadawy, Mohamed G., et al.
Publicado: (2022)

Antigenicity comparison of SARS‐CoV‐2 Omicron sublineages with other variants contained multiple mutations in RBD
por: Li, Qianqian, et al.
Publicado: (2022)

A broader neutralizing antibody against all the current VOCs and VOIs targets unique epitope of SARS-CoV-2 RBD
por: Liu, Shuo, et al.
Publicado: (2022)

Preclinical immunological evaluation of an intradermal heterologous vaccine against SARS-CoV-2 variants
por: Fan, Shengtao, et al.
Publicado: (2022)

SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape
por: Li, Qianqian, et al.
Publicado: (2021)

Development of a Bioluminescent Imaging Mouse Model for SARS-CoV-2 Infection Based on a Pseudovirus System
por: Wu, Xi, et al.
Publicado: (2023)

Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617
por: Fan, Lin-qian, et al.
Publicado: (2021)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

The unreversible reduced but persistent activated NK and CD8(+) T cells in severe/critical COVID-19 during omicron pandemic in China
por: Qin, Ling, et al.
Publicado: (2023)

Development of a Triple-Color Pseudovirion-Based Assay to Detect Neutralizing Antibodies against Human Papillomavirus
por: Nie, Jianhui, et al.
Publicado: (2016)

HIV-1 pseudoviruses constructed in China regulatory laboratory
por: Nie, Jianhui, et al.
Publicado: (2019)

Head-to-head comparisons of the neutralizing antibody against SARS-CoV-2 variants elicited by four priming-boosting regimens
por: Jiang, Hu-Dachuan, et al.
Publicado: (2022)

Aggregation of high‐frequency RBD mutations of SARS‐CoV‐2 with three VOCs did not cause significant antigenic drift
por: Li, Tao, et al.
Publicado: (2022)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2021)

Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617
por: Peng, Lei, et al.
Publicado: (2022)

Single cell characteristics of patients with vaccine-related adverse reactions following inactivated COVID-19 vaccination
por: Jiang, Manling, et al.
Publicado: (2023)

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants
por: Edara, Venkata-Viswanadh, et al.
Publicado: (2021)

Impact of B.1.617 and RBD SARS-CoV-2 variants on vaccine efficacy: An in-silico approach
por: Ranjan, Prashant, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

The surgions mate, 1617
Publicado: (1979)

An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry
por: Lin, Xi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vogr7r3bgetnht583ov6hmlecm